{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T18:16:57Z","timestamp":1774117017638,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T00:00:00Z","timestamp":1491350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["NKP-332-019"],"award-info":[{"award-number":["NKP-332-019"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10198-017-0887-5","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T13:21:47Z","timestamp":1491398507000},"page":"341-353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation"],"prefix":"10.1007","volume":"19","author":[{"given":"Dirk","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Rhiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Stollenwerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Borsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Schmutzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Stock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,5]]},"reference":[{"issue":"4","key":"887_CR1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","volume":"1","author":"Global Burden of Disease Cancer Collaboration","year":"2015","unstructured":"Global Burden of Disease Cancer Collaboration: The global burden of cancer 2013. JAMA Oncol 1(4), 505\u2013527 (2015)","journal-title":"JAMA Oncol"},{"key":"887_CR2","unstructured":"Robert-Koch Institut, Zentrum f\u00fcr Krebsregisterdaten: Brustkrebs (Mammakarzinom). \n                        http:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Brustkrebs\/brustkrebs_node.html\n                        \n                     (2015). Accessed 28 Apr2016"},{"issue":"6","key":"887_CR3","doi-asserted-by":"publisher","first-page":"R156","DOI":"10.1186\/bcr3369","volume":"14","author":"K Rhiem","year":"2012","unstructured":"Rhiem, K., Engel, C., Graeser, M., et al.: The risk of contralateral breast cancer in patients from BRCA1\/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 14(6), R156 (2012). doi:\n                        10.1186\/bcr3369","journal-title":"Breast Cancer Res."},{"issue":"12","key":"887_CR4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","volume":"14","author":"R Luengo-Fernandez","year":"2013","unstructured":"Luengo-Fernandez, R., Leal, J., Gray, A., et al.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14(12), 1165\u20131174 (2013). doi:\n                        10.1016\/S1470-2045(13)70442-X","journal-title":"Lancet Oncol"},{"key":"887_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3870","author":"RA Willems","year":"2015","unstructured":"Willems, R.A., Bolman, C.A., Mesters, I., et al.: Cancer survivors in the first year after treatment: the prevalence and correlates of unmet needs in different domains. Psycho-oncology (2015). doi:\n                        10.1002\/pon.3870","journal-title":"Psycho-oncology"},{"issue":"1","key":"887_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1017\/S026646231100064X","volume":"28","author":"SV Sorensen","year":"2012","unstructured":"Sorensen, S.V., Goh, J.W., Pan, F., et al.: Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int. J. Technol. Assess. Health Care 28(1), 12\u201321 (2012). doi:\n                        10.1017\/S026646231100064X","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"6","key":"887_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ctrv.2010.12.008","volume":"37","author":"TS Foster","year":"2011","unstructured":"Foster, T.S., Miller, J.D., Boye, M.E., et al.: The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat. Rev. 37(6), 405\u2013415 (2011). doi:\n                        10.1016\/j.ctrv.2010.12.008","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"887_CR8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1200\/JCO.2010.32.1075","volume":"29","author":"DE Cohn","year":"2011","unstructured":"Cohn, D.E., Kim, K.H., Resnick, K.E., et al.: At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 29(10), 1247\u20131251 (2011). doi:\n                        10.1200\/JCO.2010.32.1075","journal-title":"J Clin Oncol"},{"key":"887_CR9","unstructured":"Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer. National Institute for Health and Clinical Excellence: Guidance. Cardiff (UK) (2013)"},{"key":"887_CR10","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplin\u00e4re S3-Leitlinie f\u00fcr die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Langversion 3.0, Aktualisierung 2012, AWMF-Register-Nummer: 032\u2013045OL"},{"issue":"4","key":"887_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/M13-1684","volume":"160","author":"HD Nelson","year":"2014","unstructured":"Nelson, H.D., Pappas, M., Zakher, B., et al.: Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann. Intern. Med. 160(4), 255\u2013266 (2014). doi:\n                        10.7326\/M13-1684","journal-title":"Ann. Intern. Med."},{"issue":"25","key":"887_CR12","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","volume":"31","author":"KA Phillips","year":"2013","unstructured":"Phillips, K.A., Milne, R.L., Rookus, M.A., et al.: Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 31(25), 3091\u20133099 (2013). doi:\n                        10.1200\/JCO.2012.47.8313","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"887_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10549-010-1043-4","volume":"125","author":"VR Grann","year":"2011","unstructured":"Grann, V.R., Patel, P.R., Jacobson, J.S., et al.: Comparative effectiveness of screening and prevention strategies among BRCA1\/2-affected mutation carriers. Breast Cancer Res. Treat. 125(3), 837\u2013847 (2011). doi:\n                        10.1007\/s10549-010-1043-4","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"887_CR14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-144-6-200603210-00006","volume":"144","author":"K Anderson","year":"2006","unstructured":"Anderson, K., Jacobson, J.S., Heitjan, D.F., et al.: Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann. Intern. Med. 144(6), 397\u2013406 (2006)","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"887_CR15","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejca.2008.02.025","volume":"44","author":"J Norum","year":"2008","unstructured":"Norum, J., Hagen, A.I., Maehle, L., et al.: Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur. J. Cancer 44(7), 963\u2013971 (2008). doi:\n                        10.1016\/j.ejca.2008.02.025","journal-title":"Eur. J. Cancer"},{"key":"887_CR16","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen: Allgmeine Methoden. Version 4.2 vom 22.04.2015. \n                        https:\/\/www.iqwig.de\/download\/IQWiG_Methoden_Version_4-2.pdf\n                        \n                     (2015). Accessed 28 Apr 2016"},{"issue":"2","key":"887_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10198-010-0292-9","volume":"13","author":"M Schad","year":"2012","unstructured":"Schad, M., John, J.: Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis. Eur. J. Health Econ 13(2), 127\u2013144 (2012). doi:\n                        10.1007\/s10198-010-0292-9","journal-title":"Eur. J. Health Econ"},{"issue":"1","key":"887_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/CEJ.0b013e3283552e28","volume":"22","author":"T Chen","year":"2013","unstructured":"Chen, T., Jansen, L., Gondos, A., et al.: Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage. Eur. J. Cancer Prev. 22(1), 59\u201367 (2013). doi:\n                        10.1097\/CEJ.0b013e3283552e28","journal-title":"Eur. J. Cancer Prev."},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/1471-2407-12-317","volume":"12","author":"B Holleczek","year":"2012","unstructured":"Holleczek, B., Brenner, H.: Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany. BMC Cancer 12, 317 (2012). doi:\n                        10.1186\/1471-2407-12-317","journal-title":"BMC Cancer"},{"key":"887_CR20","unstructured":"German Consortium for Hereditary Breast and Ovarian Cancer. \n                        http:\/\/www.krebshilfe.de\/wir-helfen\/adressen\/familiaerer-krebs\/brustkrebszentren.html\n                        \n                     (2016). Accessed 28 Apr 2016"},{"key":"887_CR21","unstructured":"The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Chapter 13: Including non-randomized studies. \n                        http:\/\/handbook.cochrane.org\/chapter_13\/13_including_non_randomized_studies.htm\n                        \n                     (2011). Accessed 31 Jan 2017"},{"issue":"3","key":"887_CR22","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10549-011-1819-1","volume":"131","author":"LH Land","year":"2012","unstructured":"Land, L.H., Dalton, S.O.: Jensen, et al.: impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990\u20132008. Breast Cancer Res. Treat. 131(3), 1013\u20131020 (2012). doi:\n                        10.1007\/s10549-011-1819-1","journal-title":"Breast Cancer Res. Treat."},{"issue":"21","key":"887_CR23","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck, T.R., Lynch, H.T., Neuhausen, S.L., et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346(21), 1616\u20131622 (2002). doi:\n                        10.1056\/NEJMoa012158","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"887_CR24","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek, S.M., Friebel, T.M., Singer, C.F., et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9), 967\u2013975 (2010). doi:\n                        10.1001\/jama.2010.1237","journal-title":"JAMA"},{"issue":"11","key":"887_CR25","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat, N., Peock, S., Frost, D., et al.: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl. Cancer Inst. 105(11), 812\u2013822 (2013). doi:\n                        10.1093\/jnci\/djt095","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"887_CR26","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1245\/s10434-010-1136-7","volume":"17","author":"JC Boughey","year":"2010","unstructured":"Boughey, J.C., Hoskin, T.L., Degnim, A.C., et al.: Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann. Surg. Oncol. 17(10), 2702\u20132709 (2010). doi:\n                        10.1245\/s10434-010-1136-7","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"887_CR27","first-page":"283","volume":"5","author":"VR Grann","year":"1999","unstructured":"Grann, V.R., Jacobson, J.S., Sundararajan, V., et al.: The quality of life associated with prophylactic treatments for women with BRCA1\/2 mutations. Cancer J Sci Am 5(5), 283\u2013292 (1999)","journal-title":"Cancer J Sci Am"},{"issue":"1","key":"887_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-009-0373-6","volume":"119","author":"VR Grann","year":"2010","unstructured":"Grann, V.R., Patel, P., Bharthuar, A., et al.: Breast cancer-related preferences among women with and without BRCA mutations. Breast Cancer Res. Treat. 119(1), 177\u2013184 (2010). doi:\n                        10.1007\/s10549-009-0373-6","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"887_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/erp.10.65","volume":"10","author":"T Peasgood","year":"2010","unstructured":"Peasgood, T., Ward, S.E., Brazier, J.: Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res 10(5), 553\u2013566 (2010). doi:\n                        10.1586\/erp.10.65","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"887_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","volume":"113","author":"LJ Havrilesky","year":"2009","unstructured":"Havrilesky, L.J., Broadwater, G., Davis, D.M., et al.: Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol. Oncol. 113(2), 216\u2013220 (2009). doi:\n                        10.1016\/j.ygyno.2008.12.026","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"887_CR31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jval.2012.05.003","volume":"15","author":"R Ara","year":"2012","unstructured":"Ara, R., Wailoo, A.: Using health state utility values in models exploring the cost-effectiveness of health technologies. Value Health 15(6), 971\u2013974 (2012). doi:\n                        10.1016\/j.jval.2012.05.003","journal-title":"Value Health"},{"key":"887_CR32","unstructured":"Federal Statistical Office of Germany: Life expectancy 2015. \n                        https:\/\/www.destatis.de\/EN\/FactsFigures\/SocietyState\/Population\/Deaths\/Deaths.html\n                        \n                     (2015). Accessed 28 Apr 2016"},{"issue":"1","key":"887_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10549-010-1336-7","volume":"127","author":"K Metcalfe","year":"2011","unstructured":"Metcalfe, K., Lynch, H.T., Ghadirian, P., et al.: Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 127(1), 287\u2013296 (2011). doi:\n                        10.1007\/s10549-010-1336-7","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"887_CR34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(12)70042-6","volume":"13","author":"S Litiere","year":"2012","unstructured":"Litiere, S., Werutsky, G., Fentiman, I.S., et al.: Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20\u00a0year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 13(4), 412\u2013419 (2012). doi:\n                        10.1016\/S1470-2045(12)70042-6","journal-title":"Lancet Oncol."},{"issue":"24","key":"887_CR35","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","volume":"25","author":"WE Winter","year":"2007","unstructured":"Winter, W.E., Maxwell, G.L., Tian, C., Gynecologic Oncology Group Study, et al.: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25(24), 3621\u20133627 (2007)","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"887_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck, T.R., Friebel, T., Lynch, H.T., et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 22(6), 1055\u20131062 (2004). doi:\n                        10.1200\/JCO.2004.04.188","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"887_CR37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.mlr.0000172050.67085.4f","volume":"43","author":"PW Sullivan","year":"2005","unstructured":"Sullivan, P.W., Lawrence, W.F., Ghushchyan, V.: A national catalog of preference-based scores for chronic conditions in the United States. Med. Care 43(7), 736\u2013749 (2005)","journal-title":"Med. Care"},{"issue":"17","key":"887_CR38","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.2165\/11538150-000000000-00000","volume":"70","author":"S Dawood","year":"2010","unstructured":"Dawood, S.: Triple-negative breast cancer: epidemiology and management options. Drugs 70(17), 2247\u20132258 (2010). doi:\n                        10.2165\/11538150-000000000-00000","journal-title":"Drugs"},{"issue":"7","key":"887_CR39","doi-asserted-by":"publisher","first-page":"e70680","DOI":"10.1371\/journal.pone.0070680","volume":"8","author":"B Holleczek","year":"2013","unstructured":"Holleczek, B., Jansen, L., Brenner, H.: Breast cancer survival in Germany: a population-based high resolution study from Saarland. PLoS One 8(7), e70680 (2013). doi:\n                        10.1371\/journal.pone.0070680","journal-title":"PLoS One"},{"issue":"2","key":"887_CR40","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-012-2366-0","volume":"137","author":"KR Hess","year":"2013","unstructured":"Hess, K.R., Esteva, F.J.: Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res. Treat. 137(2), 449\u2013455 (2013). doi:\n                        10.1007\/s10549-012-2366-0","journal-title":"Breast Cancer Res. Treat."},{"key":"887_CR41","doi-asserted-by":"publisher","first-page":"137304","DOI":"10.1155\/2014\/137304","volume":"2014","author":"EC Inwald","year":"2014","unstructured":"Inwald, E.C., Ortmann, O., Zeman, F., et al.: Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry. Biomed. Res. Int. 2014, 137304 (2014). doi:\n                        10.1155\/2014\/137304","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"887_CR42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2217\/cer.12.43","volume":"1","author":"M DeKoven","year":"2012","unstructured":"DeKoven, M., Bonthapally, V., Jiao, X., et al.: Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey. J Comp Eff Res 1(5), 453\u2013463 (2012). doi:\n                        10.2217\/cer.12.43","journal-title":"J Comp Eff Res"},{"issue":"2","key":"887_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10549-007-9550-7","volume":"107","author":"A Dufresne","year":"2008","unstructured":"Dufresne, A., Pivot, X., Tournigand, C., et al.: Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res. Treat. 107(2), 275\u2013279 (2008). doi:\n                        10.1007\/s10549-007-9550-7","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"887_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.seminoncol.2008.12.003","volume":"36","author":"LP Martin","year":"2009","unstructured":"Martin, L.P., Schilder, R.J.: Management of recurrent ovarian carcinoma: current status and future directions. Semin. Oncol. 36(2), 112\u2013125 (2009). doi:\n                        10.1053\/j.seminoncol.2008.12.003","journal-title":"Semin. Oncol."},{"issue":"14","key":"887_CR45","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1517\/14656566.8.14.2293","volume":"8","author":"SC Modesitt","year":"2007","unstructured":"Modesitt, S.C., Jazaeri, A.A.: Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin. Pharmacother. 8(14), 2293\u20132305 (2007). doi:\n                        10.1517\/14656566.8.14.2293","journal-title":"Expert Opin. Pharmacother."},{"issue":"7","key":"887_CR46","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000315699","volume":"33","author":"MP Lux","year":"2010","unstructured":"Lux, M.P., Reichelt, C., Wallwiener, D., et al.: Results of the Zometa cost-utility model for the German healthcare system based on the results of the ABCSG-12 study. Onkologie 33(7), 360\u2013368 (2010). doi:\n                        10.1159\/000315699","journal-title":"Onkologie"},{"key":"887_CR47","unstructured":"Universit\u00e4tsklinikum M\u00fcnster DRG Research Group Medizinisches Management: Webgrouper. \n                        http:\/\/drg.uni-muenster.de\/index.php?option=com_webgrouper&view=webgrouper&Itemid=26\n                        \n                     (2015). Accessed 28 Apr 2016"},{"key":"887_CR48","unstructured":"Rote Liste\u00ae Service GmbH: Rote Liste. \n                        http:\/\/www.rote-liste.de\/\n                        \n                     (2015). Accessed 28 Apr 2016"},{"key":"887_CR49","unstructured":"Kassen\u00e4rztliche Bundesvereinigung: Uniform value scale. \n                        http:\/\/www.kbv.de\/html\/ebm.php\n                        \n                     (2015). Accessed 28 Apr 2016"},{"issue":"10","key":"887_CR50","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s00520-014-2253-9","volume":"22","author":"A Arican","year":"2014","unstructured":"Arican, A., Bozkurt, T., Bozcuk, H., et al.: A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support. Care Cancer 22(10), 2629\u20132634 (2014). doi:\n                        10.1007\/s00520-014-2253-9","journal-title":"Support. Care Cancer"},{"key":"887_CR51","unstructured":"Verband der Ersatzkassen: Rahmenvertr\u00e4ge und Verg\u00fctungslisten bei Heilmitteln.. \n                        http:\/\/www.vdek.com\/vertragspartner\/heilmittel\/rahmenvertrag.html\n                        \n                     (2015). Accessed 28 Apr 2016"},{"key":"887_CR52","unstructured":"IntelliMed GmbH.:Catalog of therapeutic products. \n                        http:\/\/www.heilmittelkatalog.de\/heilmittelkatalog-online.html\n                        \n                     (2014). Accessed 28 Apr 2016"},{"key":"887_CR53","unstructured":"Statistisches Bundesamt. GENESIS-Online Datenbank. \n                        https:\/\/www-genesis.destatis.de\/genesis\/online;jsessionid=131E6809880313E767FC8E952532F25D.tomcat_GO_1_3?operation=previous&levelindex=2&levelid=1479294919749&step=2\n                        \n                     (2016). Accessed 31 Jan 2017"},{"issue":"1","key":"887_CR54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0266462301104083","volume":"17","author":"DG Fryback","year":"2001","unstructured":"Fryback, D.G., Chinnis Jr., J.O., Ulvila, J.W.: Bayesian cost-effectiveness analysis. An example using the GUSTO trial. Int. J. Technol. Assess. Health Care 17(1), 83\u201397 (2001)","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"2 Suppl","key":"887_CR55","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","volume":"18","author":"AA Stinnett","year":"1998","unstructured":"Stinnett, A.A., Mullahy, J.: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Decis. Making 18(2 Suppl), S68\u2013S80 (1998)","journal-title":"Med. Decis. Making"},{"issue":"2","key":"887_CR56","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1245\/s10434-006-9206-6","volume":"14","author":"AM Geiger","year":"2007","unstructured":"Geiger, A.M., Nekhlyudov, L., Herrinton, L.J., et al.: Quality of life after bilateral prophylactic mastectomy. Ann. Surg. Oncol. 14(2), 686\u2013694 (2007). doi:\n                        10.1245\/s10434-006-9206-6","journal-title":"Ann. Surg. Oncol."},{"issue":"13","key":"887_CR57","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jama.2014.5985","volume":"313","author":"TR Rebbeck","year":"2015","unstructured":"Rebbeck, T.R., Mitra, N., Wan, F., et al.: Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13), 1347\u20131361 (2015). doi:\n                        10.1001\/jama.2014.5985","journal-title":"JAMA"},{"issue":"2","key":"887_CR58","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","volume":"148","author":"X Chai","year":"2014","unstructured":"Chai, X., Friebel, T.M., Singer, C.F., et al.: Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 148(2), 397\u2013406 (2014). doi:\n                        10.1007\/s10549-014-3134-0","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"887_CR59","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1023\/A:1013123915272","volume":"10","author":"M Cappelli","year":"2001","unstructured":"Cappelli, M., Surh, L., Humphreys, L., et al.: Measuring women\u2019s preferences for breast cancer treatments and BRCA1\/BRCA2 testing. Qual. Life Res. 10(7), 595\u2013607 (2001)","journal-title":"Qual. Life Res."},{"issue":"2","key":"887_CR60","first-page":"829","volume":"34","author":"T Hildebrandt","year":"2014","unstructured":"Hildebrandt, T., Thiel, F.C., Fasching, P.A., et al.: Health utilities in gynecological oncology and mastology in Germany. Anticancer Res. 34(2), 829\u2013835 (2014)","journal-title":"Anticancer Res."},{"issue":"7","key":"887_CR61","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/hec.1086","volume":"15","author":"D Parkin","year":"2006","unstructured":"Parkin, D., Devlin, N.: Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ. 15(7), 653\u2013664 (2006). doi:\n                        10.1002\/hec.1086","journal-title":"Health Econ."},{"issue":"2","key":"887_CR62","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10198-004-0264-z","volume":"6","author":"W Greiner","year":"2005","unstructured":"Greiner, W., Claes, C., Busschbach, J.J., von der Schulenburg, J.M.: Validating the EQ-5D with time trade off for the German population. Eur. J. Health Econ. 6(2), 124\u2013130 (2005)","journal-title":"Eur. J. Health Econ."},{"issue":"1","key":"887_CR63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1006\/gyno.2001.6345","volume":"83","author":"YM Chan","year":"2001","unstructured":"Chan, Y.M., Ngan, H.Y., Li, B.Y., et al.: A longitudinal study on quality of life after gynecologic cancer treatment. Gynecol. Oncol. 83(1), 10\u201319 (2001). doi:\n                        10.1006\/gyno.2001.6345","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"887_CR64","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.ejca.2011.10.020","volume":"48","author":"M Heijer den","year":"2012","unstructured":"den Heijer, M., Seynaeve, C., Timman, R., et al.: Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study. Eur. J. Cancer 48(9), 1263\u20131268 (2012). doi:\n                        10.1016\/j.ejca.2011.10.020","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"887_CR65","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/pon.3039","volume":"22","author":"M Heijer den","year":"2013","unstructured":"den Heijer, M., Seynaeve, C., Vanheusden, K., et al.: Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. Psycho-Oncology 22(3), 598\u2013604 (2013). doi:\n                        10.1002\/pon.3039","journal-title":"Psycho-Oncology"},{"issue":"1","key":"887_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1897-4287-12-9","volume":"12","author":"GW Hooker","year":"2014","unstructured":"Hooker, G.W., King, L., Vanhusen, L., et al.: Long-term satisfaction and quality of life following risk reducing surgery in BRCA1\/2 mutation carriers. Hered Cancer Clin Pract 12(1), 9 (2014). doi:\n                        10.1186\/1897-4287-12-9","journal-title":"Hered Cancer Clin Pract"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-017-0887-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-017-0887-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-017-0887-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T23:28:17Z","timestamp":1521674897000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-017-0887-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,5]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s10198-017-0887-5","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,5]]}}}